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Objective/Methods.Todeterminetheoutcomesofinvasiveneonatalcandidiasisbeforeinstitutionofroutineantifungalprophylaxis,
we conducted a retrospective review of cases of invasive candidiasis in newborns in a referral-based neonatal intensive care unit
located in a single tertiary academic center between January 1998and December 2002.Results. Sixty-three newborns with invasive
neonatal candidiasis were identiﬁed. Overall mortality rate was 35%. Virtually every infant had a central venous catheter (CVC),
required mechanical ventilation and previous administration of antibacterial agents. Delayed institution of antifungal therapy
was associated with increased mortality. In addition, length of hospitalization,duration of prior antibacterial therapy, mechanical
ventilation,and CVCuse, as well as evidence ofend-organ disease,were associatedwithanadverse outcome.Conclusions.R e l i a n c e
on available laboratory tools in cases of invasive neonatal candidiasis can result in delayed diagnosis and increased mortality. A
r i s k - f a c t o r - b a s e da p p r o a c ht oe m p i r i c a lt r e a t m e n tc o u l db ej u s t i ﬁ e di nt h i ss e t t i n g .
1.Introduction
Invasive fungal infections are a major problem in the neona-
tal intensive care unit (NICU). Candida species are as the
fourth most common cause of late-onset infections in the
neonatal intensive care unit (NICU) and are responsible for
considerable morbidity and mortality [1]. About 12% of all
neonatal infections are due to Candida species [2–4]; cases
increased 10-fold between 1981 and 1995 [5, 6]. Reported
mortality rates for infants with invasive neonatal candidiasis
are between 25 and 50%,compared to an overall mortality of
4.7% for all NICU admissions [5].
Major risk factors associated with invasive neonatal can-
didiasis include extreme prematurity, prolonged central ve-
nous catheterization, and prolonged use of broad-spectrum
antibacterial agents [7–12].
Blood cultures are still considered as the gold standard
for the diagnosis of invasive neonatal candidiasis. However,
when compared with bacterial pathogens, their sensitivity is
less than ideal. In a large report of autopsy-proven invasive
candidiasis [13], the majority ofcases lackeda positive blood
culture. In a cohort of 41 patients with hematologic malig-
nancies and autopsy-proven candidiasis, 28% of those who
had single-organ involvement had a previous positive blood
culture. When at least 3 organs were found to be infected
in postmortem examination, sensitivity of blood cultures
increased to 78% [14]. The blood volumes necessary to
optimize organism recovery are not easily attainable in ne-
onates [15, 16]. Therefore, relying solely in blood cultures
could underestimate the true incidence of invasive neonatal
candidiasis. The absence of a fungal pathogen isolated in a
blood culture may lead to underdiagnosis of invasive neo-
natal candidiasis, and in turn, to a delay in treatment institu-
tion, which could contribute to the high mortality observed
in previous studies [1, 2, 9].
We assessed for the eﬀect of delayed recognition and
treatment ofinvasiveneonatalcandidiasis andforriskfactors
associated with mortality in a tertiary care NICU over the
ﬁve-year period before the institution of routine ﬂuconazole
prophylaxis in our NICU.2 International Journal of Pediatrics
2.Materialsand Methods
2.1.StudyDesign. Weconductedaretrospective cohortstudy
of all cases of culture-proven invasive neonatal candidiasis
admitted to the NICU at the UCLA Medical Center between
January 1, 1998 and December 31, 2002.
2.2. Population. Study participants were identiﬁed from mi-
crobiologyrecordsofall infants admitted tothe NICUwith a
positivefungal culture.Casesofinvasive neonatalcandidiasis
weredeﬁnedasthosethatfulﬁlled thefollowing criteria(1)+
(2a) or (1) + (2b):
(1) a clinical picture compatible with fungal sepsis, de-
ﬁned by patients meeting at least 5 criteria [17]: ad-
mission to an NICU with high rate of candidemia,
history of broad-spectrum antibiotic coverage, use of
a third-generation cephalosporin negative bacterial
blood culture results, a falling platelet count, use of
systemic steroids, NPO, need for mechanical ventila-
tion, and cardiovascular instability requiring pressor
support;
(2a) a fungal pathogen isolated from blood culture either
from a line or peripheral site, urine by bladder cath-
eterization, peritoneal ﬂuid by paracentesis, pleural
ﬂuid by pleurocentesis;
(2b) when the only fungal isolate came from a deep aspi-
rate from an endotracheal tube, patients had to fulﬁll
clinical criteria for sepsis and all 4 of the follow-
ing clinical criteria for pneumonia (radiographic
changes, need for increase in mechanical ventilation,
increase in tracheal secretions, abnormal peripheral
white blood cell count and/or bandemia).
The analysis was conducted comparing survivors with non-
survivors. In cases of multiple fungal infections in a single
patient, data was analyzed from the ﬁnal episode in order to
evaluate the primary outcome. Survival was deﬁned as either
discharge to home or transfer to a lower level of care.
2.3. Data. Medical records were reviewed, and information
was obtained on gender,birth weight, gestational age,under-
lying illness, hospital course, invasive procedures, outcome,
use of anti-infective agents, and bacterial infections.
2.4. Statistics. Data are presented descriptively for demo-
graphics, culture location and species of fungus responsible
for infection. Student’s t-test was used to compare single
variable diﬀerences between mortality and survival to dis-
charge groups. Multivariate analysis was used to identify sig-
nificant associations of risk factors. Discrete data was com-
pared by Chi-square or Fisher exact test.
3.Results
Between January 1, 1998 and December 31, 2002, there were
1686 admissions to the UCLA NICU. There were 157 deaths,
for an overall mortality rate of 9.3%. We identiﬁed a total of
253 patients with a positive fungal culture. From these, 63
patients met our deﬁnition for invasive neonatal candidiasis,
for a prevalence of 37 cases/1000 admissions. 22 of the 63
infants expired, for an overall mortality of 35%.
The mean gestational age (GA) of both the infants who
expired and survived invasive neonatal candidiasis was 30
weeks (range: 23–40 weeks). Mean birth weight (BW) was
1628 grams (range: 409–4470) in patients who expired and
1741 grams (range 486–3800) in survivors. In the survivor
group, 10 patients (24%) had GA between 23 and 25 weeks
and 13 patients (32%) had GA of 26–34 weeks, compared
with 7 (31%) and 4 (18%), respectively, in the mortality
group.
10 survivors (24%) had congenital heart disease, com-
pared with 5 (23%) infants in the mortality group. 3 sur-
vivors (7%) had other major congenital anomalies, com-
pared with 3 nonsurvivors (14%). 5 survivors (12%) and 3
nonsurvivors (14%) were diagnosed with chromosomal
anomalies. There were no signiﬁcant diﬀerences in primary
diagnoses between survivor and mortality groups. All but
one of the 63 patients received mechanical ventilation and
antibacterial agents. Allpatients had central venous catheters
placed. A previous, culture-proven bacterial infection was
identiﬁed in 27 survivors (66%) and 18 nonsurvivors (82%)
(P = 0.25).
DemographicsandantibacterialuseareshowninTables1
and 2. Both groups diﬀered signiﬁcantly in mean number of
positive fungal cultures, days with central venous catheters,
mean platelet count nadir, days in NICU before invasive
fungal infection, days on ventilator (both total and prior to
fungalinfection),previoususeofathird-generationcephalo-
sporin, and days of treatment with intravenous antibacterial
agents prior to fungal infections. Mean duration of positive
cultures, GA, birth weight, total ICU days, and days of
antifungal therapy were comparable between those infants
who expired and those who survived until discharge.
The most common isolates identiﬁed were Candida albi-
cans (57%) and Candida parapsilosis (27%), followed by
Candida tropicalis (5%), Candida lusitaniae (3%), Candida
glabrata (2%), and Malassezia furfur (2%). An unidentiﬁed
yeast was isolated in 2 cases (3%).
We did not ﬁnd an association between fungal species
and outcome of invasive fungal infections. We did not ob-
serve a signiﬁcant diﬀerence in culture sites between the
survivor and mortality groups (Table 3). Multivariate anal-
ysis demonstrated a higher risk of mortality with increasing
number of positive fungal cultures as well as the number of
daysofantibioticuse priortothe fungal infection (P = 0.005
and 0.009, resp.).
Our population included 23 patient with blood isolates;
of these, 15 had the CVC removed after the positive blood
culture,11/15(73%)survived.3of8(38%)patientsinwhich
the CVC was not removed survived (P = 0.09).
Thirty-three patients had further diagnostic studies per-
formed (head/cardiac/renal/abdominal ultrasound or oph-
thalmologic exam). Of these, 8 (24%) had evidence of inva-
sive fungal disease. Of the 8 infants with end-organ evidence
of fungal disease, 3 had only blood cultures positive and
5 had positive fungal cultures at multiple sites. 6 of theseInternational Journal of Pediatrics 3
Table 1: Mortality risk factors: comparison between nonsurvivor and survivor groups.
Nonsurvivors
n = 22
Survivors
n = 41
P value
Number of positive fungal cultures, mean 5.0 2.6 0.001
Platelet count nadir during IFI: 1000 cells/mm3,m e a n 38 73 0.01
NICU stay at time of ﬁrst positive fungal culture (mean, days) 69.5 32.8 0.004
Postconceptional age at time of positive culture (mean, weeks) 35.1 40.5 0.03
Gestational Age
≤26 10 19
27–32 16
33–37 65
Term 51 1
Gender
Male 13 17
Female 92 4
Congenital heart disease
Yes 51 0
No 17 31
Age (days) at time of ﬁrst positive fungal culture
≤14 41 4
15–28 41 0
29–60 41 2
61–120 64
>120 41
Time on mechanical ventilation before ﬁrst positive fungal culture (mean, days) 46.0 21.6 0.002
Time with CVC before ﬁrst positive fungal culture (mean, days) 60.1 31.1 0.001
Time with urinary catheter before ﬁrst positive fungal culture (mean, days) 7.5 14.4 0.06
Time between ﬁrst positive culture and initiation of therapy (median, days) 42 0.001
Table 2: Antibacterial use: comparison between mortality and survivor groups.
Nonsurvivors
n = 22
Survivors
n = 41
P value
Days on antibacterial drugs before ﬁrst positive fungal culture: mean 36.3 17.3 0.002
Total days on antibacterial drugs: mean 63.9 40 0.006
Antibacterial agents used before invasive fungal infection
Glycopeptides (vancomycin) (%) 20 (91) 28 (68) 0.06
Aminoglycosides (amikacin,gentamicin, tobramycin) (%) 18 (82) 29 (71) 0.34
3rd generation cephalosporins (cefotaxime, ceftazidime) (%) 21 (95) 26 (63) 0.003
Carbapenem (imipenem/cilastatin, meropenem) (%) 8 (36) 8 (19.5) 0.16
Anaerobic (clindamycin, metronidazole) (%) 6 (27) 6 (15) 0.32
Table 3: Origin of positive culture specimen: comparison between mortality and survivor groups.
Culture site Nonsurvivors
n = 18 (%)
Survivors
n = 33 (%)
P value
Blood (only isolate) 3 (17) 9 (50) 0.52
Blood (single or multiple isolates) 9 (50) 15 (45) 0.79
Tracheal aspiration (only) 4 (18) 8 (20) 1.0
Urine catheterization (only) 2 (11) 9 (27) 0.30
Peritoneal or pleural ﬂuid (only) 2 (11) 3 (17) 1.0
2 or more positive sites 11 (61) 12 (36) 0.174 International Journal of Pediatrics
8 infants expired (75%). In contrast, 6/25 (24%) patients
who had no end-organ evidence of fungal disease expired
(P<0.01). Of these, 9 patients had multiple positive sites;
in 7 the only source was urine, in 4 peritoneal ﬂuid, 3 had
only positive blood cultures, and 2 only tracheal cultures.
Seven of the 25 patients who expired (28%) underwent
postmortem examination. 5 of these 7 had autopsy evidence
of invasive fungal disease and a positive postmortem culture.
Two patients had ischemic colitis and Candida peritonitis.
They were 25- and 26-week premature infants, respectively,
and each had treatment started 4 days after the ﬁrst positive
culture. One patient had Candida albicans isolated from
blood, urine, and peritoneal cultures. No radiographic eval-
uation was done. The second patient had negative renal and
abdominal ultrasounds obtained after peritoneal ﬂuid
yielded Candida parapsilosis. All other sites were negative in
this infant. The third patient was a full-term infant with
congenital heart disease who had autopsy evidence of Can-
dida sepsis, with involvement of the heart, liver, and kid-
neys. Treatment was begun 3 days after blood cultures were
positive for Candida albicans. No other sites were positive,
and no radiologic evaluation was undertaken. The fourth
patientwas a 24-week premature infant who had renal myce-
tomas on autopsy. This patient had many negative blood
and urine fungal cultures; the only positive culture isolated
camefrom atracheal aspiratewhich waspositiveforCandida
lusitaniae. Treatment was begun 4 days after the ﬁrst isolate
was identiﬁed. One baby had gastroschisis and a peritoneal
culture with Candida albicans. Microabscesses were identi-
ﬁed in postmortem examination of the peritoneal cavity;
however, postmortem cultures were negative. Treatment was
initiated 4 days after isolation of the organism. No end-
organ evaluation was done. 2 patients had negative autopsy
culture ﬁndings; both were 24-week premature infants.
One had Candida parapsilosis in tracheal aspirates, and the
other had had Candida parapsilosis in tracheal aspirates and
urine.
We found a signiﬁcant association between delay of anti-
fungal administration and mortality. Median time to initi-
ation of treatment after the ﬁrst positive fungal culture was
obtained was 4 days in the mortality group and 2 days in the
survivor group (P = 0.004). When we analyzed the relation-
ship between mortality and the interval from the day the
ﬁrst positive culture was drawn and the day that antifungal
therapy was started, we found mortality rates of 22.5%
(7/30), 40% (6/15), and 54% (7/13) when those intervals
were 0–2 days, 2–7 days, and >7 days, respectively. Each 24-
hour delay in the initiation of antifungal therapy was associ-
ated with a 10.9% increase in odds of mortality (OR 1.109,
95% CI: 1.003–1.226). When we exclude patients in which
the only positive culture was obtained by tracheal aspirate,
median times to treatment initiation are 4 days for the
mortality group and 1 day for survivors (P = 0.02). Time
from culture to treatment was similar in patients without
a blood fungal isolate and fungemic patients. Similarly, we
did not observe a signiﬁcant diﬀerence in the distribution
of culture sites in those patients in which therapy was
delayed over 48 hours when compared with those infants
who received antifungals earlier.
Fifty-eight of 63 patients (92%) received systemic anti-
fungal therapy with either amphotericin B deoxycholate or
amphotericin B lipid complex. Of the 5 patients who did
not receive therapy, 3 survived, and two expired. Three had
Candida albicans,a n d2h a dCandida parapsilosis.T h e i rG A
ranged from 25 to 40 weeks, and the diagnoses were as fol-
lows: chromosomal anomalies in one baby, prematurity in
two infants, congenital heart disease in one patient, and
noncardiac congenital anomalies in one subject. The source
of isolates in the patients who expired was tracheal only in
one patient and urine plus tracheal aspirate in one infant. In
survivors, isolates came from peritoneal ﬂuid in two infants
and urine in one patient.
4.Discussion
We believe that the observation of increased mortality in pa-
tients where a longer interval ensued between obtaining cul-
tures and stating antifungal therapy is important. Although
certainly not surprising, an association between delay in
initiation of antifungal therapy and mortality has not been
documented previously in the literature. In severe infections,
one can expect a more favorable outcome when therapy
is promptly instituted. However, there is an inherent delay
between the clinical presentation of sepsis, when cultures are
presumably obtained, and the availability of results. A study
by Schelonka and Moser [18] suggested that candidemia can
be detected within 72 hours. A septic-appearing newborn
routinely receives antibacterial agents at the time of clinical
presentation. Incontrast, many clinicians will onlystart anti-
fungal therapy when a positive culture is reported or when
the patient fails to improve after a period of antibacterial
agents. In a retrospective study, Makhoul et al. [6]r e p o r t e d
49 cases of neonatal candidemia over a 10-year period, with
no deaths. This was attributed to a policy of starting empiric
antifungal therapy immediately after obtaining cultures in
neonateswith risk factorsforfungal sepsis, instead ofwaiting
for culture results. Benjamin Jr. et al. [19]e v a l u a t e dd a t a
from a multicenter cohort to develop a model to provide
guidance to neonatologists as to when to consider empirical
antifungal therapy.
We did not identify an association between culture site
and therapy delay, which could potentially result in a clini-
cianbiasagainst nonbloodisolates. Moreover,wedidnotob-
serve a diﬀerence in mortality rates by culture sites. Patients
in whom the only source for the fungal pathogen was a tra-
cheal culture had a similar outcome to the remainder of
the study population. Tracheal cultures are interpreted by
many clinicians with skepticism, due to a concern about a
perceivedpoorcorrelationbetweentrachealisolateandlower
respiratory tract pathogens.This in turncouldleadto adelay
in initiating antifungal therapy. Several studies have found
correlation between isolation of Candida in tracheal cultures
anditspresenceinlungparenchymaorthesubsequentriskof
candidemia in neonates [20–22]. In a septic-appearing new-
born with ﬁndings of clinical pneumonia, when a bacterial
pathogen is not found, or when empiric antibacterial ther-
apy fails to create a clinical response, one may consider thatInternational Journal of Pediatrics 5
the presence of a fungal isolate in a tracheal aspirate should
be considered a true pathogen, and speciﬁc therapy should
be instituted.
The patients who died had onset of infection at a mean
of 69 days versus 33 days in the survivors. This conﬂicts with
data presented previously from a review of a private practice
database [23], which reported that a younger age at the time
of infection is associated with mortality. This could be due
to the inherent selection bias in patient complexity observed
in large, tertiary referral institutions, when compared with
community-based practices.
AlthoughCandida albicans was the most common isolate
recovered, our data conﬁrm the emergence of non-albicans
speciesasmajorcausesofinvasiveneonatalcandidiasis[1,2].
We did not ﬁnd a correlation between fungal species and
mortality. In a study of 45 cases of neonatal candidiasis over
a 10-year period, Faix [24] reported that 7 of 29 infants with
Candida albicans d i e d ,c o m p a r e dt on od e a t h si n1 6i n f a n t s
with Candida parapsilosis. The relatively large number of
Candida parapsilosis found in newborns could be due to
the known propensity of Candida parapsilosis to adhere to
foreign material [17, 24, 25]. It has been suggested that the
high prevalenceofCandida parapsilosis reﬂects theaggressive
use of intravascular devices in NICUs. There is evidence
that Candida parapsilosis is commonly carried on the hands
of health care workers [25]. Transmission from infected
mothers is unlikely to account for the unusual prevalence of
thisorganism in neonates, since Candida parapsilosis israrely
seen on vaginal cultures, whereas Candida glabrata, ac o m -
mon vaginal isolate, is an uncommon causeof candidemia in
infants and children [26, 27]. We did not identify any cases
of invasive neonatal candidiasis due to Candida krusei.O t h e r
species, such as Candida lusitaniae and Candida tropicalis,
were uncommon in our study population, as observed by
others [1]. It should be noted that ﬂuconazole prophylaxis
was not used in our study population.
The previous use of a third-generation cephalosporin
antibiotic was associated with mortality in our study pop-
ulation. In our study population, these agents (cefotaxime
and ceftazidime) were used empirically in virtually all cases.
Third-generation cephalosporins have been previously iden-
tiﬁed as risk factors for acquisition of an invasive fungal
pathogen [6, 10, 11, 17]. Duration of prior antibacterial
therapy was doubled in our nonsurvivor population. This is
consistent with previous observations [17, 28]. The number
of positive fungal cultures, time in the NICU, and total time
of mechanical ventilation were all increased in nonsurvivors.
The relationship between multiple positive cultures and
outcomehas beenreported previously [29, 30]. Severalother
studies have illustrated the link between duration of intuba-
tion and length of NICU hospitalization with emergence of
fungal sepsis [8, 9, 31].
The presence of suggestive imaging studies and multiple
positive fungal cultures were predictive of mortality in in-
fants with fungal sepsis in our population. End-organ in-
volvement and multiple positive cultures have been shown
to be markers for treatment failure and predictors of disease
severity [29, 31]. Our study had the unique feature of an
unusuallyhighrateofautopsiesperformed,whichconﬁrmed
the presence of gross pathology ﬁndings of invasive fungal
disease in 5 neonates, including ischemic fungal colitis in
2 patients, peritoneal microabscesses in one patient, renal
mycetomas in one neonate, and multiple organ involvement
in one infant.
These data have the limitations inherent to a single-
center, retrospective study, therefore we were unable to an-
swer questions about the reasons for delay in initiation of
antifungal therapy. However, given the degree of diﬃculty
in the diagnosis of neonatal candidiasis, its increasing inci-
dence, and the delay of fungal cultures, we believe that a
risk-factor-based approach to empirical treatment could be
justiﬁed in a sick appearing newborn.
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